131
Participants
Start Date
November 14, 2022
Primary Completion Date
July 19, 2023
Study Completion Date
August 1, 2023
LY3857210
Administered orally
Placebo
Administered orally
Altoona center for clinical research, Duncansville
North Georgia Clinical Research, Woodstock
Accel Research Sites- Clinical Research Unit, DeLand
Synexus Clinical Research US, Inc - Orlando, Orlando
Suncoast Research Group, Miami
University of Miami Don Suffer Clinical Research Building, Miami
New Horizon Research Center, Miami
Synexus Clinical Research US, Inc., Pinellas Park
Renstar Medical Research, Ocala
META Medical Research Institute, Dayton
Great Lakes Research Group, Inc., Bay City
Lillestol Research, Fargo
Northwestern University, Chicago
StudyMetrix Research, City of Saint Peters
Clinvest Headlands Llc, Springfield
Synexus Clinical Research - St. Petersburg, San Antonio
FutureSearch Trials of Neurology, Austin
Rocky Mountain Clinical Research, Idaho Falls
Arizona Research Center, Phoenix
Synexus Clinical Research US, Inc., Chandler
Artemis Institute for Clinical Research, San Diego
Artemis Institute for Clinical Research, Riverside
Northwest Clinical Research Center, Bellevue
Rainier Clinical Research Center, Renton
CMR of Greater New Haven, LLC, Hamden
Boston Clinical Trials, Boston
ActivMed Practices and Research, Methuen
MedVadis Research Corporation, Waltham
Ponce Medical School Foundation Inc., Ponce
Latin Clinical Trial Center, San Juan
Eli Lilly and Company
INDUSTRY